1-3 of 3
Ingrid Caras
Close
Sort by
Journal Articles

Phase I Study of Elotuzumab (HuLuc63) in Phase I Study of Elotuzumab (HuLuc63) in Relapsed/Refractory Multiple Myeloma

Jeffrey A. Zonder, Seema Singhal, William Bensinger, Ann Mohrbacher, Mohamad A. Hussein, Nikhil C. Munshi, Ingrid Caras, Anil Singhal, Frits van Rhee
Journal: Blood
Blood (2008) 112 (11): 2773.
https://doi.org/10.1182/blood.V112.11.2773.2773
Published: 2008
Journal Articles

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

Yu-Tzu Tai, Myles Dillon, Weihua Song, Merav Leiba, Xian-Feng Li, Peter Burger, Alfred I. Lee, Klaus Podar, Teru Hideshima, Audie G. Rice, Anne van Abbema, Lynne Jesaitis, Ingrid Caras, Debbie Law, Edie Weller, Wanling Xie, Paul Richardson, Nikhil C. Munshi, Claire Mathiot, Hervé Avet-Loiseau, Daniel E. H. Afar, Kenneth C. Anderson
Journal: Blood
Blood (2008) 112 (4): 1329–1337.
https://doi.org/10.1182/blood-2007-08-107292
Published: 2008
Includes: Supplemental data
Journal Articles

Eradication of Tumors in Pre-Clinical Models of Multiple Myeloma by Anti-CS1 Monoclonal Antibody HuLuc63: Mechanism of Action Studies.

Audie Rice, PhD, Myles Dillon, B.S., Anne van Abbema, M.S., Lynne Jesaitis, Ph.D, Melanie Wong, M.Sc., Stacey Lawson, B.S., Gao Liu, M.S., Yin Zhang, M.S., David Powers, PhD, Susan Rhodes, B.Sc., Ingrid Caras, PhD, Debbie Law, PhD, Daniel Afar, PhD
Journal: Blood
Blood (2006) 108 (11): 3503.
https://doi.org/10.1182/blood.V108.11.3503.3503
Published: 2006